{"product_id":"autl-marketing-mix","title":"(AUTL) Autolus Therapeutics plc Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Autolus Therapeutics plc 4P's Marketing Mix Analysis explains the company’s product offering, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page shows a real preview\/sample of the report so you can assess style and substance before buying — purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUCATZYL obe-cel, FDA-approved CD19 CAR-T for adult ALL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUCATZYL (obe-cel) is Autolus Therapeutics plc’s first marketed therapy, an autologous CD19 CAR-T for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA approval in 2024 turned Autolus from a development-only biotech into a commercial oncology company. It is the lead product and the main near-term revenue driver, with the phase 1\/2 FELIX study reporting a 77% overall remission rate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUTO1\/22, Phase 1 pediatric relapsed or refractory ALL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUTO1\/22 extends Autolus Therapeutics plc’s CD19 CAR-T platform into pediatric relapsed or refractory ALL, a setting where ALL remains the most common childhood cancer and about 3,000 U.S. children are diagnosed each year. It targets a high-unmet-need group with few salvage options after relapse. The program also widens Autolus’s leukemia franchise beyond adults and supports a larger CD19 addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUTO4, TRBC1-targeted therapy for peripheral T-cell lymphoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUTO4 is Autolus Therapeutics plc's TRBC1-targeted T-cell therapy for peripheral T-cell lymphoma, a rare cancer that makes up about 10% to 15% of non-Hodgkin lymphoma. TRBC1 targeting aims to hit malignant T cells while sparing normal ones, which could improve selectivity versus older approaches. If successful, AUTO4 would give Autolus a second major hematology platform beyond CD19.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAUTO8, Phase I multiple myeloma candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAUTO8 is Autolus Therapeutics plc’s Phase I CAR-T candidate for multiple myeloma, a market with about 35,000 new U.S. cases a year. It widens the pipeline beyond leukemia and lymphoma, so it adds long-term diversification with limited near-term revenue impact.\u003c\/p\u003e\n\u003cp\u003eThe product sits in an early, high-risk stage, but the target is one of the largest cell-therapy oncology spaces. That makes AUTO8 a portfolio option for future growth if early safety and response data stay strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I; still early\u003c\/li\u003e\n\u003cli\u003eMultiple myeloma expands reach\u003c\/li\u003e\n\u003cli\u003eLarge oncology market\u003c\/li\u003e\n\u003cli\u003eDiversifies long-term pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAUTO6NG and AUTO5, preclinical pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAUTO6NG and AUTO5 widen Autolus Therapeutics plc’s product set beyond its lead commercial therapy. AUTO6NG targets GD2 in neuroblastoma, while AUTO5 is a preclinical hematology program, giving the company 2 early-stage shots on goal and a clearer path to pipeline renewal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 preclinical assets\u003c\/li\u003e\n\u003cli\u003eAUTO6NG: GD2 neuroblastoma\u003c\/li\u003e\n\u003cli\u003eAUTO5: hematology program\u003c\/li\u003e\n\u003cli\u003eSupports pipeline renewal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUCATZYL Drives Autolus’s First Commercial Growth Phase\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAUCATZYL is Autolus Therapeutics plc’s lead product and first commercial asset, a CD19 CAR-T for adult R\/R B-ALL. FELIX showed a 77% remission rate, and FDA approval in 2024 made it the company’s main 2025–2026 revenue driver.\u003c\/p\u003e\n\u003cp\u003eAUTO1\/22, AUTO4, AUTO8, AUTO6NG, and AUTO5 extend the pipeline into pediatric ALL, PTCL, myeloma, neuroblastoma, and hematology. That gives Autolus Therapeutics plc reach across large and rare blood-cancer niches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUCATZYL\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eAdult B-ALL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUTO4\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003ePTCL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P analysis of Autolus Therapeutics plc’s product, pricing, place, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns Autolus Therapeutics plc’s 4Ps into a quick, structured snapshot that simplifies strategic review and speeds up decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and benchmarks to speed due diligence and validate Autolus Therapeutics assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLondon, United Kingdom headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc is headquartered in London, which serves as its corporate, scientific, and investor-relations base. London anchors the company in the UK biotech cluster, where the life sciences sector supports more than 300,000 jobs and benefits from deep capital access and research talent. That location helps Autolus stay close to regulators, investors, and academic partners in one of Europe’s top biotech hubs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist oncology treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUCATZYL is sold through hospital-based specialist oncology centers, not retail pharmacies. CAR-T delivery needs trained teams and approved sites, and the FDA REMS model keeps access limited to certified centers. Site readiness matters because each patient gets a 1-dose infusion after leukapheresis, manufacturing, and inpatient or outpatient monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites in hematologic oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses hospital and cancer-center trial networks to move its hematologic oncology pipeline into patients, especially in leukemia, lymphoma, myeloma, and pediatric disease. These sites are the key access point before broad commercialization, with CAR-T development in this area often relying on specialized centers and inpatient capacity for cell collection, dosing, and safety follow-up. Autolus Therapeutics plc reported a 2025 product revenue base of $0 and remains driven by clinical execution and trial-site reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAutologous cell-therapy supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s autologous cell-therapy place model is a one-patient, one-batch chain: leukapheresis collects cells, cryopreservation freezes them, and cold-chain transport keeps them controlled until return. The process is time-sensitive, with vein-to-vein timelines often running about 2–4 weeks, so every handoff needs release testing and chain-of-identity checks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeukapheresis starts the chain\u003c\/li\u003e\n\u003cli\u003eCryopreservation protects cell quality\u003c\/li\u003e\n\u003cli\u003eCold chain limits temperature drift\u003c\/li\u003e\n\u003cli\u003eDistribution must stay time-critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMajor-market focus, United States and Europe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc is aimed at the two biggest oncology arenas: the United States and Europe. The U.S. is the core launch market for AUCATZYL, with about 2.0 million new cancer cases in 2024, while Europe adds scale with roughly 2.7 million new cases a year. Europe also supports later-stage clinical development and follow-on expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. = first commercial push\u003c\/li\u003e\n\u003cli\u003eEurope = growth and trials\u003c\/li\u003e\n\u003cli\u003eFocus on large blood-cancer markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Place Strategy Centers on Hospital Access and U.S. Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s Place strategy is built around London headquarters, hospital-based CAR-T centers, and a time-sensitive cold-chain network for AUCATZYL. The U.S. is the first commercial market, while Europe supports trials and later growth. In 2025, product revenue was $0, so access and site expansion remain the key place driver.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eLondon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial access\u003c\/td\u003e\n\u003ctd\u003eCertified hospital centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue 2025\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAutolus Therapeutics plc Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Autolus Therapeutics plc 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable, and ready-to-use document covering Product, Price, Place, and Promotion with actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congress presentations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus uses oncology congresses, such as ASH and EHA, to promote its CAR-T pipeline with clinical updates on efficacy, safety, and trial milestones. For a research-led biotech, these data readouts are a core Promotion channel because they shape physician trust and investor attention, especially as AUCATZYL expanded from its 2024 launch into the 2025 execution phase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases and pipeline updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses press releases and pipeline updates as a main promotion tool to flag trial progress, FDA and EMA milestones, and launch steps. It used this channel to announce AUCATZYL’s U.S. FDA approval on 8 Nov. 2024, keeping physicians, investors, and analysts aligned on one approved CAR-T product and the next pipeline readouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations and earnings calls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses quarterly results, guidance, and investor decks to show cash use, AUCATZYL launch execution, and pipeline timing. In 2025, this matters because the company must prove it can turn its CAR-T approval into sales while funding trials. Clear updates help keep market trust high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeer-reviewed medical publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeer-reviewed medical publications help Autolus Therapeutics plc turn trial data into trusted evidence, which matters in cell therapy where physicians and regulators want proof beyond press releases. Published data from studies like AUCATZYL’s clinical program support adoption by showing response, safety, and durability in a format hospitals can cite. That credibility can speed use and strengthen regulatory confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidates the platform scientifically\u003c\/li\u003e\n\u003cli\u003eSupports physician adoption\u003c\/li\u003e\n\u003cli\u003eBuilds regulatory trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialist hematology and oncology engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s promotion is a specialist, site-based model aimed at hematologists, oncologists, transplant centers, and treatment-site staff for AUCATZYL, the first FDA-approved product in its portfolio, cleared in November 2024. The message is practical: patient selection, safety monitoring for CAR-T toxicities, and logistics around referral, collection, infusion, and follow-up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets specialist prescribers, not mass consumers\u003c\/li\u003e\n\u003cli\u003eFocuses on safety and workflow training\u003c\/li\u003e\n\u003cli\u003eSupports complex CAR-T delivery at treatment sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Builds AUCATZYL Trust Through Medical Education, Not Mass Ads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc promotes AUCATZYL through hematology congresses, peer-reviewed papers, and site education, not mass-market ads. The goal is clear: build physician trust, explain CAR-T safety and workflow, and support adoption after the 8 Nov 2024 U.S. FDA approval.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASH, EHA\u003c\/td\u003e\n\u003ctd\u003eClinical data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePress releases\u003c\/td\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor decks\u003c\/td\u003e\n\u003ctd\u003eLaunch progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUCATZYL, premium hospital-based CAR-T pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAUCATZYL is priced like other CAR-T therapies: a high-cost, one-time hospital treatment, not a retail drug. In the U.S., CAR-T list prices are typically in the high six figures per infusion, and payment runs through specialist centers and payer reimbursement, often Medicare Part B or commercial case rates.\u003c\/p\u003e\n\u003cp\u003eSo Autolus Therapeutics plc is not selling through standard consumer channels. The value sits in the oncology center, where the therapy is bundled with cell collection, infusion, monitoring, and adverse-event care, which is why pricing is negotiated around hospital delivery rather than shelf price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time treatment model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses a one-time CAR-T pricing model, so the bill lands upfront instead of monthly. That fits the class: CAR-T therapies in the U.S. often sit in the mid-six-figure range per course, with value tied to deep, durable remissions rather than repeat dosing. For buyers, the key test is whether long-term response offsets the high entry price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutologous manufacturing cost base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutologous manufacturing means each dose is made from the patient’s own cells, so Autolus Therapeutics plc carries higher testing, cold-chain, and release costs than off-the-shelf drugs. That bespoke process is reflected in pricing: AUCATZYL launched in the U.S. with a list price of about $526,000 per treatment, showing how price must cover complex, patient-specific production.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer and hospital reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s net price in CAR-T is not the sticker price; it is mostly set by payer coverage, prior authorization, and hospital site reimbursement. In U.S. CAR-T, access can swing by health system and country, so reimbursement is a top commercial lever that can make or break uptake, especially for a therapy class with six-figure treatment costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage drives realized net price\u003c\/li\u003e\n\u003cli\u003ePrior auth slows patient access\u003c\/li\u003e\n\u003cli\u003eSite reimbursement shapes hospital uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline assets, no approved commercial price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc has 5 named pipeline assets here AUTO1\/22, AUTO4, AUTO8, AUTO6NG, and AUTO5 and none has an approved commercial price yet. Their price will be set only after clinical readouts and regulatory approval, so they remain development-stage assets, not revenue-priced products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 assets, no approved price\u003c\/li\u003e\n\u003cli\u003ePricing depends on trial data\u003c\/li\u003e\n\u003cli\u003eApproval comes before launch price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat means current value is driven more by pipeline progress than by marketed sales. Until approval, there is no fixed list price, so any future pricing model for Autolus Therapeutics plc must anchor on efficacy, safety, and payer access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Prices AUCATZYL at $526K, But Reimbursement Drives the Real Sale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc prices AUCATZYL as a one-time CAR-T, with a U.S. list price of about $526,000 per treatment. Realized net price depends on payer approval, hospital reimbursement, and the added cost of cell collection, infusion, and monitoring, so the sale is won at the oncology center, not at retail.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUCATZYL U.S. list price\u003c\/td\u003e\n\u003ctd\u003e~$526,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing model\u003c\/td\u003e\n\u003ctd\u003eOne-time infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice driver\u003c\/td\u003e\n\u003ctd\u003ePayer and hospital reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234137383177,"sku":"autl-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/autl-marketing-mix.webp?v=1785712092","url":"https:\/\/dcfanalyst.com\/products\/autl-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}